Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

NCT06974734 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06974734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06974734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
May 6, 2025
Completion date
March 31, 2026
Enrollment
8 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung, carcinoma, pancreatic ductal, malignant melanoma, squamous cell carcinoma of the head and neck (scchn)